Germex Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.20 M
as on 10-07-2024
- Paid Up Capital ₹ 0.10 M
as on 10-07-2024
- Company Age 22 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 6.74%
(FY 2022)
- Profit 7.01%
(FY 2022)
- Ebitda 16.34%
(FY 2022)
- Net Worth 15.14%
(FY 2022)
- Total Assets -18.76%
(FY 2022)
About Germex Pharmaceuticals
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.20 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Gurvinder Singh and Emendra Singh serve as directors at the Company.
- CIN/LLPIN
U24231DL2002PTC115604
- Company No.
115604
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2002
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
West Delhi, Delhi, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Germex Pharmaceuticals?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gurvinder Singh  | Director | 27-Aug-2003 | Current |
| Emendra Singh | Director | 23-May-2022 | Current |
Financial Performance and Corporate Structure Insights of Germex Pharmaceuticals.
Germex Pharmaceuticals Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 6.74% increase. The company also saw a slight improvement in profitability, with a 7.01% increase in profit. The company's net worth Soared by an impressive increase of 15.14%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Germex Pharmaceuticals?
In 2020, Germex Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Iboss Tech Solutions Private LimitedActive 17 years 11 monthsGurvinder Singh and Emendra Singh are mutual person
All State Financial Services Private LimitedActive 29 years 11 monthsGurvinder Singh and Emendra Singh are mutual person
Bonjour Pharmaceuticals Private LimitedActive 27 years 7 monthsGurvinder Singh and Emendra Singh are mutual person
- A To Z Printers & Publishers Private LimitedActive 15 years 2 months
Emendra Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Germex Pharmaceuticals?
Germex Pharmaceuticals has a workforce of 18 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Germex Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Germex Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
